Recent Company News

• 03:55 AM ET May 19, 2026
  

  Fosun International unit Club Med may raise minimum of $500M (HK$3.92B) from potential Hong Kong IPO - Bloomberg (HK$4.06, +0.07)

• 06:48 AM ET May 13, 2026
  

  Shanghai Fosun Pharmaceutical (Group) obtains exclusive rights from AriBio for Alzheimer's drug candidate AR1001 (HK$18.63, 0.00)

• 09:36 PM ET May 05, 2026
  

  StreetAccount Sector Summary - China Healthcare April Recap

• 10:37 AM ET Apr 28, 2026
  

  Creating a Sustainable Impact: Fosun International Releases 2025 ESG Report and Climate Information Disclosures Report

• 10:25 AM ET Apr 28, 2026
  

  Fosun International releases 2025 ESG report (HK$4.14, 0.00)

• 05:01 AM ET Apr 28, 2026
  

  Shanghai Fosun Pharmaceutical (Group) Co. reports Q1 net income attributable CNY870.8M, +14% vs year-ago CNY764.8M (HK$19.96, 0.00)

• 06:15 AM ET Apr 24, 2026
  

  EU's CHMP adopted a positive opinion, recommending a change to the terms of the marketing authorisation for BioNTech's Comirnaty ($105.56, 0.00)

• 09:07 PM ET Apr 23, 2026
  

  Shanghai Fosun Pharmaceutical (Group) Co. initiated overweight at Northeast Securities (23-Apr, timing uncertain) (CNY 25.57, 0.00)

• 04:49 AM ET Apr 21, 2026
  

  Shanghai Fosun Pharmaceutical (Group) Co. releases 2025 ESG report (HK$20.10, 0.00)